Table 1

Baseline characteristics of treated patients

		n=55	%
Age (median, range)		53	(25–73)
ECOG PS	0	34	62
	1	18	33
	≥2	3	5
Stage	IIIB	2	4
	M1a	4	7
	M1b	6	11
	M1c	43	78
Elevated LDH		34	62
BRAF mutated		32	58
No. of metastatic sites (median, range)		4	(1–8)
History of brain metastasis		7	13
History of liver metastasis		7	13
History of brain and liver metastasis		4	7
Lines of prior therapy	1	9	16
	2	28	51
	≥3	18	33
Previous therapy	Interleukin-2	33	60
	Ipilimumab	41	74
	Anti-PD-1 therapy	23	42
	Temozolomide	5	9
	BRAF inhibitor	10	18

ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PD-1, programmed cell death protein 1; PS, performance status.